Pathogenic mechanisms mediating antiphospholipid syndrome

Current Opinion in Rheumatology

Volumn 13, Issue 5, 2001, Pages 377-382

  Meroni, Pier Luigi ^a   Riboldi, Piersandro ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING DISORDER; CELL FUNCTION; FETUS WASTAGE; HEMOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MONOCYTE; PATHOGENESIS; PREGNANCY COMPLICATION; PRIORITY JOURNAL; REVIEW; THROMBOSIS; TROPHOBLAST;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; DISEASE MODELS, ANIMAL; FEMALE; FETAL DEATH; HUMANS; MICE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOSIS;

EID: 0034805912     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-200109000-00006     Document Type: Review

References (45)

1. Experimental thrombosis and antiphospholipid antibodies: New insights
2. Antiphospholipid syndrome: Insight from animal models
3. The influence of antiphospholipid antibodies on the protein C pathway
4. Binding of anticardiolipin antibodies to protein C via beta 2 glycoprotein h a possible mechanism in inhibitory effect of antiphospholipid antibodies on the protein C system
5. Differential effects of anti-beta 2 glycoprotein I and anti-prothrombin antibody on the anticoagulant activity of activated protein C
6. Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus
7. The putative mechanism of thrombosis in antiphospholipid syndrome: Impairment of the protein C and the fibrnolytic systems by monoclonal anticardiolipin antibodies
8. Reduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII
9. Plasma contact system, kallikrein/kinin system and antiphospholipid-protein antibodies in thrombosis and pregnancy
10. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant
11. Endothelial activation by aPL: A potential pathogenetic mechanism for the clinical manifestations of the syndrome
12. High affinity binding of β2- glycoprotein I to human endothelial cells is mediated by Annexin II
13. Increased endothelial cell expression of alpha3betal integrin in cardiac valvulopathy in primary (Hughes) and secondary antiphospholipid syndrome
14. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: Correlations with the severity of thrombosis
15. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo
16. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin
17. Human β2-glycoprotein I binds to endothelial cells through a cluster of lysine residues that are critical for anionic phospholipid binding and offers epitopes for anti-β2glycoprotein I antibodies
18. Endothelial cells as a target for antiphospholipid antibodies: Role of anti-beta 2 glycoprotein I antibodies
19. Autoantibodies associated with atherosclerosis
20. Adoptive transfer of beta(2)- glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice
21. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome
22. Antiphospholipid antibody-mediated disruption of the annexin-V antithrombotic shield; a thrombogenic mechanism for the antiphospholipid syndrome
23. Anti-beta 2 glycoprotein I (GPI) autoantibodies, annexin V binding and the anti-phospholipid syndrome
24. Competition of annexin V and anticardiolipin antibodies for binding to phosphatidylserine containing membranes
25. Interaction between antiphospholipid antibodies and eicosanoids
26. Arterial disease and thrombosis in the antiphospholipid syndrome: A pathogenic role for endothelin 1
27. Interaction of anti-phospholipid antibodies with late endosomes of human endothelial cells
28. Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome
29. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes
30. Analysis of prothrombotic effects of two human monoclonal IgG antiphospholipid antibodies of apparently similar specificity
31. Monocyte tissue factor induction via activation of beta 2 glycoprotein I specific T lymphocytes is associated with thrombosis and fetal loss in patients with antiphospholipid antibodies
32. Tissue factor pathway and the antiphospholipid syndrome
33. International consensus statement on preliminary classification for definite antiphospholipid syndrome
34. Long-term prognosis of antiphospholipid syndrome in patients with systemic lupus erythematosus
35. Mechanisms of thrombosis in the antiphospholipid syndrome: Binding to platelets
36. Platelet activation markers and the primary antiphospholipid syndrome (PAPS)
37. Determinants of enhanced thromboxane biosynthesis in patients with systemic lupus erythematosus
38. IgG from patients with antiphospholipid syndrome binds to platelets without induction of platelet activation
39. Effect of anticardiolipin/beta2glycoprotein I complexes on production of thromboxane A2 by platelets from patients with the antiphospholipid syndrome
40. Beta 2 glycoprotein I containing immune-complexes in lupus patients: Association with thrombocytopenia and lipoprotein (a) levels
41. Placentation, antiphospholipid syndrome and pregnancy outcome
42. Affinity purified human antiphospholipid antibodies bind normal term placenta
43. The role of placental trophoblast in the pathophysiology of the antiphospholipid antibody syndrome
44. Action of anticardiolipin and antibodies to beta 2 glycoprotein I on trophoblast proliferation as a mechanism for fetal death
45. Antiphospholipid antibodies affect trophoblast gonadotrophin secretion and invasiveness by binding directly and through adhered beta 2 glycoprotein I